Skip to content
Subscriber Only

Boehringer, Pfizer’s Spiriva Mist Inhaler May Up Death Risk

Boehringer Ingelheim GmbH and Pfizer Inc.’s Spiriva mist inhaler for chronic lung disease may raise the risk of an early death, a review of five studies found.

The use of Spiriva administered in mist form was associated with a 52 percent increase in the risk of mortality, compared with patients given only a placebo, according to the review published today in the British Medical Journal. The analysis included five clinical trials involving more than 6,500 patients.